Repligen Corporation $RGEN Stock Sold by Conestoga Capital Advisors LLC

Repligen logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Conestoga Capital Advisors cut its Repligen stake by 28.6% in the third quarter, selling 280,357 shares. It still held 700,626 shares, worth about $134.7 million, making Repligen its third-largest portfolio position.
  • Repligen beat quarterly earnings and revenue estimates: EPS was $0.53 versus $0.46 expected, while revenue reached $209.3 million and rose 10.9% year over year.
  • Analyst sentiment was broadly positive, with a “Moderate Buy” consensus and an average price target of $178.57; 97.64% of the company’s stock was held by institutional investors.
  • Five stocks to consider instead of Repligen.

Conestoga Capital Advisors LLC decreased its position in Repligen Corporation (NASDAQ:RGEN - Free Report) by 28.6% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 700,626 shares of the biotechnology company's stock after selling 280,357 shares during the period. Repligen makes up 4.1% of Conestoga Capital Advisors LLC's portfolio, making the stock its 3rd largest position. Conestoga Capital Advisors LLC owned approximately 1.24% of Repligen worth $134,681,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the company. Associated Banc Corp acquired a new position in Repligen in the third quarter valued at about $226,000. Integrity Alliance LLC. acquired a new stake in shares of Repligen during the third quarter worth about $306,000. Oregon Public Employees Retirement Fund raised its position in shares of Repligen by 6.9% during the third quarter. Oregon Public Employees Retirement Fund now owns 11,691 shares of the biotechnology company's stock worth $2,247,000 after purchasing an additional 750 shares during the period. Factory Mutual Insurance Co. acquired a new stake in shares of Repligen during the third quarter worth about $1,762,000. Finally, Virtue Capital Management LLC bought a new position in shares of Repligen during the 3rd quarter valued at about $202,000. Institutional investors own 97.64% of the company's stock.

Repligen Stock Down 0.0%

NASDAQ:RGEN opened at $178.20 on Thursday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 8.43 and a current ratio of 9.88. The company has a market cap of $11.39 billion, a PE ratio of -848.53, a PEG ratio of 3.05 and a beta of 1.11. Repligen Corporation has a 52-week low of $100.99 and a 52-week high of $198.87. The stock has a 50-day simple moving average of $177.75 and a 200 day simple moving average of $145.42.

Repligen (NASDAQ:RGEN - Get Free Report) last released its earnings results on Tuesday, October 27th. The biotechnology company reported $0.53 EPS for the quarter, beating the consensus estimate of $0.46 by $0.07. Repligen had a positive return on equity of 5.49% and a negative net margin of 1.47%. The firm had revenue of $209.31 million for the quarter, compared to analysts' expectations of $206.70 million. During the same quarter in the previous year, the business posted $0.46 EPS. The business's quarterly revenue was up 10.9% compared to the same quarter last year. On average, sell-side analysts expect that Repligen Corporation will post 2.07 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on RGEN. Wells Fargo & Company boosted their price objective on Repligen from $180.00 to $185.00 and gave the company an "overweight" rating in a research report on Thursday, July 30th. UBS Group restated a "buy" rating on shares of Repligen in a report on Tuesday, September 29th. JPMorgan Chase & Co. lifted their price target on shares of Repligen from $165.00 to $175.00 and gave the company an "overweight" rating in a research note on Wednesday, July 29th. Weiss Ratings cut shares of Repligen from a "hold (c)" rating to a "sell (d+)" rating in a report on Monday. Finally, Zacks Research downgraded shares of Repligen from a "strong-buy" rating to a "hold" rating in a research report on Monday, September 28th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $178.57.

Get Our Latest Stock Analysis on RGEN

Repligen Company Profile

(Free Report)

Repligen Corporation NASDAQ: RGEN develops and manufactures bioprocessing technologies used in the production of biological medicines. Its products support key stages of biopharmaceutical manufacturing, including upstream processing, downstream purification, filtration, process monitoring and fluid management.

The company's offerings include chromatography products, filtration systems, single-use technologies, process analytics equipment and critical biological materials such as recombinant proteins.

Recommended Stories

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN - Free Report).

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Repligen Right Now?

Before you consider Repligen, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.

While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines